Abstract
Injecting drug use is the main risk of hepatitis C virus (HCV) transmission in most developed countries. HCV antiviral treatment (peginterferon-a + ribavirin) has been shown to be cost-effective for patients with no reinfection risk. We examined the cost-effectiveness of providing antiviral treatment for injecting drug users (IDUs) as compared with treating ex/non-IDUs or no treatment.
Original language | English |
---|---|
Pages (from-to) | 49-57 |
Number of pages | 9 |
Journal | Hepatology |
Volume | 55 |
Issue number | 1 |
Early online date | 6 Dec 2011 |
DOIs | |
Publication status | Published - Jan 2012 |
Keywords
- hepatitis C
- antiviral treatment
- intravenous drug users
- reinfection risk